Atea Pharmaceuticals' May 2026 quarter filings confirm full enrollment of the C-BEYOND Phase 3 trial with topline results expected mid-year, alongside ongoing enrollment in C-FORWARD scheduled for year-end data. The company is progressing toward a planned NDA submission in early 2027 for its bemnifosbuvir/ruzasvir regimen targeting hepatitis C virus infection. Supported by a strong cash position and low current liabilities, Atea maintains runway to advance late-stage development despite no commercial revenue to date. Its nucleos(t)ide prodrug strategy aims to deliver a differentiated, protease inhibitor-free, pan-genotypic oral antiviral with shorter treatment duration – potentially disrupting established HCV therapies. Key risks include regulatory uncertainties, competition from large pharmaceutical incumbents, and scaling commercialization operations.